Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NovoCure Limited - Ordinary Shares
(NQ:
NVCR
)
14.16
+0.32 (+2.31%)
Delayed Quote
Updated: 2:01 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NovoCure Limited - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
October 01, 2026
From
Novocure
Via
Business Wire
Novocure to Report Third Quarter 2026 Financial Results
October 01, 2026
From
Novocure
Via
Business Wire
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even
↗
September 18, 2026
NovoCure (NASDAQ:NVCR) outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan...
Via
MarketBeat
Novocure Announces Upcoming Investor Events
September 02, 2026
From
Novocure
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
July 23, 2026
Gainers NovoCure (NASDAQ:NVCR) shares moved upwards by 27.7% to $19.88 during Thursday's regular session. The market value of their outstanding shares is at $1.8 billion. The company's, Q2 earnings...
Via
Benzinga
Novocure (NASDAQ:NVCR) Rallies 13% on Earnings Beat as High Growth Stock Nears Profitability
↗
July 23, 2026
Via
Chartmill
Topics
Earnings
Novocure (NASDAQ: NVCR) Q1 Revenue Beat and Path to Profitability Drive 9% Share Jump
↗
April 30, 2026
Via
Chartmill
The market is filled with gapping stocks in Thursday's session.
↗
July 23, 2026
Via
Chartmill
Transcript: NovoCure Q2 2026 Earnings Conference Call
↗
July 23, 2026
NovoCure (NASDAQ:NVCR) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For...
Via
Benzinga
Topics
Earnings
NovoCure Q2 Earnings Call Highlights
↗
July 23, 2026
NovoCure (NASDAQ:NVCR) reported record second-quarter 2026 net revenue and active patient levels, with management pointing to growth across its approved products and improved expense discipline as it...
Via
MarketBeat
Topics
Earnings
Novocure Reports Second Quarter 2026 Financial Results
July 23, 2026
From
Novocure
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
July 14, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
July 07, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Novocure to Report Second Quarter 2026 Financial Results
July 01, 2026
From
Novocure
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
June 30, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
June 30, 2026
From
Novocure
Via
Business Wire
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?
↗
June 24, 2026
AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.
Via
The Motley Fool
Topics
Artificial Intelligence
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
↗
June 22, 2026
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
Via
The Motley Fool
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
June 20, 2026
From
The Schall Law Firm
Via
Business Wire
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
↗
June 19, 2026
Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.
Via
The Motley Fool
Thursday's session: gap up and gap down stocks
↗
June 18, 2026
Via
Chartmill
These stocks that are showing activity before the opening bell on Thursday.
↗
June 18, 2026
Via
Chartmill
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
June 18, 2026
From
Novocure
Via
Business Wire
CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing
↗
June 09, 2026
This oncology device innovator, known for its tumor-treating technologies, reported a notable insider sale in its latest SEC filing.
Via
The Motley Fool
Topics
Regulatory Compliance
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
↗
May 30, 2026
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.
Via
The Motley Fool
Topics
Regulatory Compliance
3 Overlooked Stocks Set to Soar in 2026
↗
May 05, 2026
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
Via
The Motley Fool
NovoCure (NVCR) Q1 2026 Earnings Transcript
↗
April 30, 2026
NovoCure (NVCR) Q1 2026 Earnings Transcript
Via
The Motley Fool
Topics
Supply Chain
Thursday's session: gap up and gap down stocks
↗
April 30, 2026
Via
Chartmill
Novocure Reports First Quarter 2026 Financial Results
April 30, 2026
From
Novocure
Via
Business Wire
Novocure to Report First Quarter 2026 Financial Results
April 01, 2026
From
Novocure
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
